LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | SNS-032 | 10 | uM | LJP6 | 2 | H13 | 72 | hr | 1401 | 1061 | 4095 | 0.2591 | -0.1647 |
| SK-BR-3 | SNS-032 | 10 | uM | LJP6 | 3 | H13 | 72 | hr | 1401 | 1203 | 4272 | 0.2816 | -0.0906 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 1 | G24 | 72 | hr | 1401 | 1545 | 4139 | 0.3733 | 0.0644 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 2 | G24 | 72 | hr | 1401 | 1400 | 4095 | 0.3419 | -0.0007 |
| SK-BR-3 | Afatinib | 0.04 | uM | LJP6 | 3 | G24 | 72 | hr | 1401 | 1367 | 4272 | 0.3200 | -0.0154 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 1 | G23 | 72 | hr | 1401 | 1536 | 4139 | 0.3711 | 0.0604 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 2 | G23 | 72 | hr | 1401 | 1378 | 4095 | 0.3365 | -0.0109 |
| SK-BR-3 | Afatinib | 0.12 | uM | LJP6 | 3 | G23 | 72 | hr | 1401 | 1335 | 4272 | 0.3125 | -0.0298 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 1 | G22 | 72 | hr | 1401 | 1484 | 4139 | 0.3585 | 0.0373 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 2 | G22 | 72 | hr | 1401 | 1450 | 4095 | 0.3541 | 0.0222 |
| SK-BR-3 | Afatinib | 0.37 | uM | LJP6 | 3 | G22 | 72 | hr | 1401 | 1269 | 4272 | 0.2970 | -0.0599 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 1 | G21 | 72 | hr | 1401 | 1487 | 4139 | 0.3593 | 0.0386 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 2 | G21 | 72 | hr | 1401 | 1583 | 4095 | 0.3865 | 0.0819 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 3 | G21 | 72 | hr | 1401 | 1653 | 4272 | 0.3869 | 0.1081 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 1 | G20 | 72 | hr | 1401 | 1325 | 4139 | 0.3201 | -0.0353 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 2 | G20 | 72 | hr | 1401 | 1587 | 4095 | 0.3875 | 0.0837 |
| SK-BR-3 | Afatinib | 3.33 | uM | LJP6 | 3 | G20 | 72 | hr | 1401 | 1740 | 4272 | 0.4073 | 0.1440 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 1 | G19 | 72 | hr | 1401 | 1221 | 4139 | 0.2950 | -0.0845 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 2 | G19 | 72 | hr | 1401 | 1210 | 4095 | 0.2955 | -0.0906 |
| SK-BR-3 | Afatinib | 10 | uM | LJP6 | 3 | G19 | 72 | hr | 1401 | 1239 | 4272 | 0.2900 | -0.0738 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 1 | H24 | 72 | hr | 1401 | 3418 | 4139 | 0.8258 | 0.7694 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 2 | H24 | 72 | hr | 1401 | 3269 | 4095 | 0.7982 | 0.7289 |
| SK-BR-3 | GSK1904529A | 0.04 | uM | LJP6 | 3 | H24 | 72 | hr | 1401 | 3329 | 4272 | 0.7792 | 0.7126 |
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 1 | H23 | 72 | hr | 1401 | 3679 | 4139 | 0.8889 | 0.8547 |
| SK-BR-3 | GSK1904529A | 0.12 | uM | LJP6 | 2 | H23 | 72 | hr | 1401 | 3558 | 4095 | 0.8688 | 0.8262 |